Prophylaxis and Treatment of COVID-19

Inclusion Criteria: 1. Population A: Symptomatic SARS-CoV-2 or ILI Cases (hospitalized and non- hospitalized) 1. Age ≥ 18 years old 2. Presence of one or more of the following symptoms at enrollment: * Stuffy or runny nose * Hoarse voice * Sore throat * Difficulty breathing * Cough * Fatigue (Low energy or tiredness) * Muscle or body aches * Headache * Fever (documented temperature \> 38°C \[100.4°F\]) or subjective fever * Chills or shivering * Feeling hot or feverish * Nausea * Vomiting * Diarrhea * Loss of smell * Loss of taste 3. Positive molecular or antigen diagnostic test for SARS-CoV-2 at study enrollment or within ≤ 5 days prior to enrollment 4. Symptom onset ≤ 5 days prior to enrollment OR 1. Age ≥ 18 years old 2. Meets the World Health Organization ILI case definition: An acute respiratory illness with a measured temperature of ≥ 38° C and cough, with onset within the past 10 days 2. Population B: SARS-CoV-2 or ILI Contacts 1. Age ≥ 18 years old 2. Asymptomatic contact of an individual with laboratory confirmed SARS-CoV-2 infection or an individual meeting the ILI case definition defined as: * Indoor exposure to the symptomatic case or cases within 6 feet (2 meters) for ≥ 15 minutes over a 24-hour period without the use of personal protective equipment 3. For SARS-CoV-2 contacts: Negative screening SARS-CoV-2 molecular or antigen diagnostic test performed at screening or within ≤ 24 hours of enrollment 4. Exposure and enrollment within 6 days or less from when the symptomatic, confirmed SARS-CoV-2 or ILI case first had symptoms Exclusion Criteria: 1. Population A: Adults seeking care or testing for SARS-CoV-2 or ILI a. Laboratory confirmed SARS-CoV-2 infection 6 to 90 days prior to enrollment 2. Population B: Adult contacts of SARS-CoV-2 or ILI infected individuals 1. Symptoms attributed to COVID-19 or ILI as assessed by a medical provider 2. Positive molecular or antigen test for SARS-CoV-2 from any upper respiratory specimen within 90 days prior to enrollment 3. SARS-CoV-2 vaccination within 90 days prior to enrollment EXCEPT if severely immunocompromised or a known vaccine non-responder * Severely immunocompromised or a known vaccine non-responder defined as: solid organ or stem cell recipient, B cell leukemia, receiving B cell depletion therapy (e.g., rituximab), agammaglobulinemia, or negative serology ≥ 2 weeks after vaccination with two doses of a vaccine 4. Positive PCR test for acute respiratory infection including but not limited to influenza, RSV, adenovirus, parainfluenza virus, rhinovirus, metapneumovirus, Bordatella Pertussis, Chlamydia Pneumonia, coronavirus (other than SARS-CoV-2), mycoplasma within 7 days of enrollment 5. Hospital admission at the time of enrollment * Hospitalization will be defined as requiring medical care not available in an outpatient setting for greater than 24 hours. * Hospitalization for isolation or quarantine requirements or for social reasons will NOT constitute an exclusion criterion For Both populations: 1. Absence of informed consent 2. Individuals who the study investigators believe are unable to comply with the requirements of the study